Biostatistics Resource Group (BRG)

Biostatistical support for all institutional research projects is available through the Department of Biostatistics via the Biostatistics Resource Group (BRG) of The University of Texas MD Anderson Cancer Center. 

Biostatistical support includes:

• Advice on data requirements for data analysis
• Biostatistical requirements for grant applications
• Design of experiments, clinical trials and other clinical studies 
  • Clinical trial designs:
    • Phase I designs to find the maximum tolerated dose (MTD) including BOIN, TITE-BOIN, BOIN-COMB, iBOIN, etc.
    • Phase I/II designs to find the optimal biological dose (OBD) including U-BOIN, BOIN-12, BOIN-DC, etc.
    • Phase II designs for initial efficacy evaluation including BOP2, TOP, 2-Arm BOP2, Basket designs, platform designs, platform designs, etc.
    • Phase III designs for confirmative studies: Group-sequential designs
    • Sample size and power calculation
  • In-vitro and in-vivo designs:
    • Standard experimental designs including single-arm, multi-arm, factorial designs, etc.  
    • Drug combination studies
    • Sample size and power calculation          
• Design and implementation of deep learning models for imaging and -omics data
• Long-term collaborative research efforts
• Standard and innovative analyses
• Biostatistical analysis:
  • Univariate analysis: t-test, ANOVA, Wilcoxon signed-rank test, Kruskal-Wallis test, etc.
  • Multivariate analysis: MANOVA, principal component analysis, etc.
  • Regression analysis: multiple regression, logistic regression, COX regression, generalized linear model, linear mixed effect model, etc.
• Bioinformatics analysis:
  • Analysis for single-cell RNAseq data
  • Analysis for microbiome data
  • Spatial statistics